Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist Interpretation
News provided by
Share this article
Share this article
WESTMINSTER, Colo. and CAMBRIDGE, Mass., April 12, 2021 /PRNewswire/ Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced a partnership to use a clinically validated tumor expression assay utilizing RNAscope
® and tissue image analysis. In a poster shared this week at the American Association for Cancer Research (AACR) Annual Meeting 2021, the companies presented data on the validation of a Dickkopf-1 (DKK1) RNAscope chromogenic in situ hybridization (CISH) assay and digital image analysis solution.
Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle®) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and
Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
- BT7480 to be presented in a New Drugs on the Horizon session; on-track to enter the clinic in 2H 21
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a New Drugs on the Horizon session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020.
2020 Leap Highlights:
Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand
Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock
Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients